ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1263

Childhood-Onset Systemic Lupus Erythematosus In Ontario:  Long Term Outcomes In a Population-Based Cohort With Universal Health Care Coverage

Deborah M. Levy1, Nadia Gunraj2, Janet E. Pope3, J. Carter Thorne4, Wesley Fidler5, Peter B. Dent6, Johannes Roth7, Roberta A. Berard8, Murray Berall9, Astrid Guttmann10 and Earl D. Silverman11, 1Rheumatology, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 2Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 3Medicine/Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, 4Southlake Regional Health Centre, Newmarket, ON, Canada, 5Rheumatology, St. Joseph's Hospital, Thunder Bay, ON, Canada, 6McMaster University, Hamilton, ON, Canada, 7University of Ottawa, Ottawa, ON, Canada, 8Children's Hospital of Western Ontario, London, ON, Canada, 9Nephrology, Humber River Regional Hospital, Toronto, ON, Canada, 10Pediatrics, Institute for Clinical Evaluative Sciences, The Hospital for Sick Children and University of Toronto, Toronto, ON, Canada, 11Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: administrative databases, death, Lupus nephritis, Pediatric rheumatology and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects II: Pediatric Systemic Lupus Erythematosus, Pediatric Vasculitis and Pediatric Myositis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Little is known about the long-term morbidity and mortality of childhood-onset SLE (cSLE) after transition to adult care; however, linking clinical data to administrative databases enables study of previously unknown outcomes.  Our objectives were to: i) describe differences in cSLE phenotype over time; ii) determine the mortality rate; and iii) describe health care utilization trends.

Methods: A retrospective chart review of all cSLE patients (<18 years at diagnosis) diagnosed between Jan 1, 1984 and Dec 31, 2011 and followed for ≥ 1 year was conducted after contacting all pediatric and adult rheumatologists and nephrologists practicing in Ontario. Clinical data and Ontario Health Insurance Plan (OHIP) numbers were securely transferred to the Institute for Clinical Evaluative Sciences (ICES).  OHIP numbers were transformed into an encrypted ICES key number (IKN) used to link the cohort to multiple administrative datasets to determine the outcomes of interest.  Patients were stratified by era of diagnosis (1984 – 1989; 1990 – 2001; 2002 – 2011) because of available data on income and utilization, and to examine trends as immunosuppressive treatments changed over time.  Means ± standard deviations are given unless noted.

Results: IKN linkage was successful for 620 cSLE patients in this inception cohort.  The cohort was predominantly female (81%) with follow-up of 10.7 (± 7.3) years, representing 6629 person-years of disease.  Age at diagnosis was 12.8 ± 3.2, which was similar across eras.  Based on postal codes, patients were evenly distributed among the income quintiles; 18% were in the lowest and 13% in the highest quintile.  For the whole cohort, self-reported ethnicity was White 42%, Asian 24%, Black 15%, South Asian 13%, Aboriginal 1.3% and Other 4%; however there is a larger percentage of non-white patients in the most recent era (61%), likely reflecting immigration patterns. See Table for differences in distribution of clinical features over time.  There were 23 deaths for a crude mortality rate 3.7%, and standardized mortality rate of 2.8%.  Six deaths (26%) occurred in the first year following cSLE diagnosis, and 14 (61%) after transfer to adult care.  Physician office visits were frequent within the first year after diagnosis, with 23% requiring ≥ 20 visits, and 46% with 10 – 19 physician visits.  Moreover, in the first year 43% of patients had at least one emergency room visit, 38% were hospitalized at least once, and 12% required ≥ 3 hospitalizations.

Table: Clinical Features by Era of Diagnosis (*cell size <6 suppressed)

 

cSLE Cohort

(N=620)

Era of Diagnosis

p-value

1984 – 1989

(N=52)

1990 – 2001

(N=194)

2002 – 2011

(N=374)

Disease Duration (y)

10.7 ± 7.3

25.7 ± 3.4

16.0 ± 3.9

5.8 ± 2.7

 

Malar Rash (N, %)

485 (78)

44 (85)

155 (80)

286 (77)

0.32

Discoid Rash

 

<6*

12 (6)

11 (3)

0.18

Oral/Nasal Ulcers

240 (39)

24 (46)

87 (45)

129 (35)

0.03

Photosensitivity

232 (37)

26 (50)

85 (44)

121 (32)

0.004

Coombs+ Anemia

178 (29)

22 (42)

55 (28)

101 (27)

<0.001

Leukopenia

118 (19)

10 (19)

29 (15)

79 (21)

0.20

Lymphopenia

341 (55)

34 (65)

108 (56)

199 (53)

0.25

Thrombocytopenia

186 (30)

13 (25)

70 (36)

103 (28)

0.08

Arthritis

449 (72)

41 (79)

137 (70)

271 (73)

0.50

Pleuritis

96 (16)

9 (17)

39 (20)

48 (13)

0.07

Pericarditis

85 (14)

17 (33)

37 (19)

31 (8)

<0.001

Nephritis (by biopsy)

273 (44)

36 (69)

107 (55)

130 (35)

<0.001

Psychosis

 

<6*

13 (7)

41 (11)

0.23

Seizures

 

<6*

9 (5)

12 (3)

0.27

ANA

608 (98)

51 (98)

191 (99)

366 (98)

0.89

dsDNA

441 (71)

44 (85)

166 (86)

231 (62)

<0.001

ENA (Sm, Ro, La, RNP)

426 (69)

38 (73)

146 (75)

242 (65)

0.03

Antiphospholipid Abs

263 (43)

9 (17)

102 (53)

152 (41)

<0.001

Thromboembolism

 

<6*

16 (8)

13 (4)

0.04

Conclusion: The prevalences of autoantibodies and certain clinical manifestations such as lupus nephritis are declining in more recently diagnosed cSLE patients.  These differences may reflect changes in cSLE over time, earlier diagnosis or a shifting ethnicity distribution in Ontario.  For cSLE, the mortality rate is highest in the first year following diagnosis, and overall health care utilization is high.


Disclosure:

D. M. Levy,
None;

N. Gunraj,
None;

J. E. Pope,
None;

J. C. Thorne,
None;

W. Fidler,
None;

P. B. Dent,
None;

J. Roth,
None;

R. A. Berard,
None;

M. Berall,
None;

A. Guttmann,
None;

E. D. Silverman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/childhood-onset-systemic-lupus-erythematosus-in-ontario-long-term-outcomes-in-a-population-based-cohort-with-universal-health-care-coverage/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology